Jun 2026 (Q2 FY26) — Aug 14, 2026
ImmuCell Q2 FY26 — Strong Commercial Growth and Capacity Expansion
Read the full callImmuCell (ICCC) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
ImmuCell earnings: last reported Fri, 14 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 7.2 | +11.5% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 26.9 | +18.1 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 1.8 | +265.6% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Price
$10.56 −1.77% · −$0.19
Performance +62.0% 1Y
1Y: $6.52 on 14 Oct 2025 → $10.56. High $11.72 (14 Jul 2026), low $4.56 (18 Nov 2025).
- Previous close
- $10.75
- 52-week range
- $4.56 – $11.72
- One year
- +59.28%
Overview
- Symbol
- ICCC
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
ImmuCell earnings calls (ICCC)
Financials
What the filings say
Net profit, year on year: +266% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 6 | 8 | 8 | 6 | 6 | 8 | 10 | 7 |
| Operating profit | -1 | 1 | 1 | 1 | 0 | -0 | 2 | 2 |
| Operating margin | −9.6% | 8.0% | 13.8% | 8.8% | 0.4% | −0.8% | 19.0% | 26.9% |
| Other income | -0 | -0 | 0 | -0 | -0 | -3 | -0 | -0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | -1 | 1 | 1 | 1 | -0 | -3 | 2 | 2 |
| Tax rate | −0.2% | 1.2% | 0.1% | 0.4% | −3.3% | −0.1% | 0.6% | 2.4% |
| Net profit | -1 | 1 | 1 | 1 | -0 | -3 | 2 | 2 |
| EPS ($ per share) | -0.09 | — | 0.16 | 0.06 | -0.02 | — | 0.21 | 0.20 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Reserves | -1 | -3 | -4 | -4 | -6 | -12 | -14 | -15 |
| Total liabilities | 11 | 10 | 12 | 12 | 14 | 19 | 18 | 15 |
| Fixed assets | 26 | 25 | 27 | 27 | 28 | 28 | 25 | 21 |
| Investments | — | 2 | 1 | — | — | — | — | — |
| Total assets | 33 | 39 | 40 | 44 | 45 | 44 | 45 | 43 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -0 | 0 | 1 | 1 | -2 | -5 | 0 | 2 |
| Cash from investing | -2 | -3 | -3 | -2 | -4 | -2 | -0 | -1 |
| Cash from financing | 1 | 7 | 2 | 4 | 1 | 2 | 3 | -1 |
| Net cash flow | — | — | — | — | — | — | 3 | 0 |
| Capital expenditure | -2 | -1 | -4 | -3 | -4 | -2 | -0 | -1 |
| Free cash flow | -2 | -1 | -3 | -2 | -6 | -7 | -0 | 1 |
Insider filings
8 filings between Nov 25, 2025 and Jun 18, 2026.
Open market
decisions to buy or sellPurchases
$141.1K
6 purchases by 2 insiders
Sales
None
No insider sold shares.
Compensation
not trading decisions- 1
- Option exercise — converted options into shares
- 1
- Tax withheld — shares kept back by the company to cover tax
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| te Boekhorst Paul Francis Olivier | $125.5K | — | Jun 18, 2026 |
| Tomsche David Scott | $15.6K | — | Nov 25, 2025 |
Latest filings (10)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Jun 18, 2026 | te Boekhorst Paul Francis Olivier President and CEO | Purchase | 8,000 | $76.0K |
| Mar 20, 2026 | BRIGHAM MICHAEL F Director | Option exercise | 25,000 | $146.0K |
| Mar 20, 2026 | BRIGHAM MICHAEL F Director | Tax withheld | 24,052 | $146.0K |
| Dec 4, 2025 | te Boekhorst Paul Francis Olivier President and CEO | Purchase | 2,432 | $13.4K |
| Dec 3, 2025 | te Boekhorst Paul Francis Olivier President and CEO | Purchase | 3,598 | $18.2K |
| Dec 2, 2025 | te Boekhorst Paul Francis Olivier President and CEO | Purchase | 3,708 | $18.1K |
| Nov 25, 2025 | Tomsche David Scott Director | Purchase | 1,633 | $7.8K |
| Nov 25, 2025 | Tomsche David Scott Director | Purchase | 1,633 | $7.8K |
| Jun 12, 2025 | Gathagan Bryan K. Director | Purchase | 1,000 | $6.3K |
| Jun 11, 2025 | Basse Gloria F Director | Option exercise | 3,530 | $17.0K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for IMMUCELL CORP /DE/
Free account. Everything above stays public.
Write why you follow IMMUCELL CORP /DE/ and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading